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Background
UK Biobank is a well-characterised cohort of over 500 000 parti-
cipants that offers unique opportunities to investigate multiple
diseases and risk factors.
Aims
An online mental health questionnaire completed by UK Biobank
participants was expected to expand the potential for research
into mental disorders.
Method
An expert working group designed the questionnaire, using
established measures where possible, and consulting with a
patient group regarding acceptability. Case definitions were
defined using operational criteria for lifetime depression,
mania, anxiety disorder, psychotic-like experiences and self-
harm, as well as current post-traumatic stress and alcohol use
disorders.
Results
157 366 completed online questionnaires were available by
August 2017. Comparison of self-reported diagnosed mental
disorder with a contemporary study shows a similar prevalence,
despite respondents being of higher average socioeconomic
status than the general population across a range of indicators.
Thirty-five per cent (55 750) of participants had at least one
defined syndrome, of which lifetime depression was the most
common at 24% (37 434). There was extensive comorbidity
among the syndromes. Mental disorders were associated with
high neuroticism score, adverse life events and long-term illness;
addiction and bipolar affective disorder in particular were asso-
ciated with measures of deprivation.
Conclusions
The questionnaire represents a very large mental health survey
in itself, and the results presented here show high face validity,
although caution is needed owing to selection bias. Built into UK
Biobank, these data intersect with other health data to offer
unparalleled potential for crosscutting biomedical research
involving mental health.
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UK Biobank is a very large, population-based cohort study estab-
lished to identify the determinants of common life-threatening
and disabling conditions.1 Most of these conditions, such as heart
disease, stroke and mental disorders, are multifactorial, involving
multiple genes of small effect and complex relationships with envir-
onmental exposures. This means that large samples are required to
study associations between these exposures and disease, and to iden-
tify targets for treatment and prevention.2 The utility of traditional
epidemiological study designs is often limited by their focus on
single disorders or exposures and their relatively modest sample
sizes.3 UK Biobank is an open-access resource providing detailed
characterisation of over half a million people aged 40–69 years at
recruitment, with proposed long-term follow-up. Recruitment was
completed in 2010, and consent was obtained for future contact
and linkage to routinely collected health-related data, such as
those produced by the National Health Service (NHS). Baseline
measures were extensive, from family history to sensory acuity (a
searchable breakdown can be found at www.ukbiobank.ac.uk),
and the resource continues to grow. Genotyping of the whole
cohort was completed earlier this year, blood biomarkers are due
next year, and multimodal imaging is underway for 100 000 partici-
pants. Information on local environmental factors, such as air pol-
lution, is also available. The design of UK Biobank offers the
opportunity to examine a wide range of risk factors and outcomes
in a sample large enough to provide the power to detect small
effects, making UK Biobank a highly efficient resource for observa-
tional epidemiology.
The effect of mental disorders on disability and quality of life is
considerable,4 accounting for the equivalent of over 1.2 million
person years lost to disability from mental and substance use disor-
ders in England alone in 2013.5 Recent work has also highlighted the
potential detrimental effect of mental disorders on both onset and
outcome of physical disease.6–8 Having mental health phenotypes
available, in conjunction with the wealth of other data in the UK
Biobank, would offer considerable opportunities to study aetio-
logical and prognostic factors. The UK Biobank baseline data
* The original version of this article was published with an incorrect
author list. A notice detailing this has been published and the error
rectified in the online PDF and HTML version.
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collection involved limited assessment of mental health, consisting
of several questions about mood and a neuroticism scale, expanded
for the past 172 729 recruited participants with questions to allow
provisional categorisation of mood disorder;9 however, there was
considerable scope for further characterisation of mental disorders
among participants.
Outcome ascertainment
Characterisingmental disorders in a cohort such asUKBiobank poses
several challenges. First, most mental disorders manifest before 30
years of age and have fluctuating courses,10 so a ‘snapshot’ of disorder
status at one point in time, as identified by most screening tools, is
likely to be less useful than a lifetime history. Second, traditional diag-
nostic approaches to mental disorders, relying upon clinician assess-
ment at interview, would be prohibitively expensive in a cohort of
this size. Third, using self-report of diagnosis or data from record lin-
kages relies upon recognition of illness and reflects healthcare usage
patterns, whereas many people with mental disorders never seek or
receive treatment.10,11 In response to these challenges, we developed
a dual approach: secondary care record linkage for identification of
more severe illnesses such as schizophrenia,12 and self-report of symp-
toms of common mental disorders, which might not have come to
clinical attention. As part of our mental health phenotyping pro-
gramme, we therefore developed an online mental health question-
naire (MHQ) for participants to complete regarding lifetime
symptoms of mental disorders. The MHQ aimed to exploit the effi-
ciency of ‘e-surveys’13 and provide enough detail to identify mental
health disorders without the need for a clinical assessment.
The present paper aims to describe the development, imple-
mentation and results of this questionnaire. We provide descriptive
data on the numbers of UK Biobank participants meeting diagnostic
criteria for specific disorders, and on the frequency of exposure to
risk factors.We also evaluate the likely representativeness of respon-
dents by comparing respondent sociodemographic characteristics
to those of the UK population using census data, and by comparing
self-reported mental disorder diagnosis with the Health Survey for
England (HSE) data.14 This will assist researchers considering or
undertaking epidemiological research to evaluate the potential
and power of using UK Biobank to look at mental health.
Method
Questionnaire development
A mental health research reference group formed of approximately
50 individuals (see Supplementary Appendix 1, available at https://
doi.org/10.1192/bjo.2018.12) participated in discussions about a
strategy for mental health phenotyping in UK Biobank, including
a workshop in January 2015. From this, a smaller steering group
was established and led the development of the MHQ. The group
recommended that the MHQ should concentrate on depression,
as it was likely to represent the greatest burden in the cohort, with
some questions about other common disorders, including anxiety,
alcohol misuse and addiction, plus risk factors for mental disorder
not captured at participants’ baseline assessment.
The intention was to create a composite questionnaire from pre-
viously existing and validated measures, taking into account partici-
pant acceptability (time, ease of use and ensuring questions were
unlikely to offend), scope for collaborations with international
studies (e.g. the Psychiatric Genomics Consortium) through
making results comparable, and the need to balance depth and
breadth of phenotyping. The basis of the questionnaire was the
measurement of lifetime depressive disorder using the Composite
International Diagnostic Interview Short Form (CIDI-SF),15
modified to provide lifetime history, as used to identify cases and
controls for some existing studies in the Psychiatric Genomics
Consortium. The CIDI-SF uses a branching structure with screen-
ing questions and skip-rules to limit detailed questions to the rele-
vant areas for each participant. Other measures were then added to
this, as summarised in Supplementary Table SM1. Where the group
were unable to find existing measures that fulfilled these criteria,
questions were written or adapted, as indicated in SM1. These sec-
tions have not been externally validated, but the questions can be
seen, along with the full questionnaire, on the UK Biobank
website (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=22) for
researchers to evaluate how they wish to use them.
Testing and ethical approval
The use of branching questions in the MHQ means that those with
established andmultiplemental disordershave a longer,moredetailed,
questionnaire. To improve acceptability in this group, we worked with
a patient advisory group at the National Institute of Health Research
(NIHR) Biomedical Research Centre at the South London and
Maudsley (SLaM) NHS Foundation Trust in designing the question-
naire and invitation.16 We then piloted the questionnaire among an
online cohort of 14 836 volunteers aged over 50 and living in the
UK, who completed the questionnaire as part of signing up to take
part in the Platform for Research Online to investigate Genetics and
Cognition in Ageing (PROTECT).17 Of those who started the ques-
tionnaire, 98.8% completed it, taking a median time of 15 min. Some
PROTECT participants commented that they wanted the opportunity
to explainwhy they felt they had experienced symptoms of depression.
In response to this, we added a question to the depression section on
loss or bereavement, and a free-text box – neither were designed to
change diagnostic algorithms, but may add to future analyses.
The questionnaire was approved as a substantial amendment to
UK Biobank by the North West – Haydock Research Ethics
Committee, 11/NW/0382.
Administration to UK Biobank participants
We incorporated the final MHQ into the UK Biobank web question-
naire platform and presented it to participants as an online question-
naire entitled ‘thoughts and feelings’. We sent participants who had
agreed to email contact a hyperlink to their personalised questionnaire.
The invitation explained the importance of collecting further informa-
tion aboutmental health and emphasised thatUKBiobankwas unable
to respond to concerns raised by the participant in the questionnaire,
instead directing them to several sources of potential support.
Participants could skip questions they preferred not to answer, and
they could save answers to return to the questionnaire later. We sent
reminder emails at 2 weeks and 4 months to those who had not
started or had partially completed the questionnaire. The MHQ will
continue to be available on the participant area of the UK Biobank
website, and the annual postal newsletter contains an invitation to
log on to the participant area and complete the MHQ, to reach those
for whom no email contact was possible. Data from this questionnaire
will therefore continue to accrue. The current numbers and aggregate
data can be accessed from the public data showcase (http://biobank.
ctsu.ox.ac.uk/crystal/label.cgi?id=136). More detail on the roll out
and associated communications can be found on the UK Biobank
website (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=22).
Defining cases from the MHQ
Case definitions for the evaluation of the responses to the MHQ are
detailed in Supplementary Appendix 2. They arose either from the
instruments used in theMHQ or by consensus criteria agreed by the
working committee who wrote the MHQ. Diagnostic criteria were
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evaluated for depression (major depressive disorder), hypomania or
mania, generalised anxiety disorder, alcohol use disorder, and
post-traumatic stress disorder (PTSD). Addiction to substances
and/or behaviour was defined based on self-report alone. Unusual
experiences (describing potential symptoms of psychosis) and
self-harm were also defined as phenomena that are important for
phenotyping, but not disorder specific. We combined outcomes to
divide the cohort into five mood disorder groups, as shown in
Supplementary Figure MD1.
Fulfilling the diagnostic criteria based on a self-report question-
naire did not allow us to rule out other psychiatric disorders, or psy-
chological or situational factors that might better explain the
symptoms and may have been elicited in a clinical evaluation.
Therefore, we regarded any case classification arising from the
MHQ as ‘likely’ rather than confirmed psychiatric disorder. The
issue becomes particularly problematic for disorders that are less
common in the population, such as bipolar affective disorder,
where the literature shows that using questionnaires to screen the
population may over-estimate prevalence.18 Therefore, although
we reported the presence of hypomania/mania symptoms for the
whole population, we only made the likely diagnosis of bipolar
affective disorder in people with a history of depression, a sub-
population where the prevalence of bipolar affective disorder is
higher, and therefore screening questionnaires have better positive
predictive values.19
Analysis and data sharing
Data were supplied by UK Biobank on 8th August 2017 under appli-
cation number 16577. We used R version 3.4.0 and MS Excel for
analyses. We reported numbers and proportions within the
sample and did not attempt to give population prevalence estimates.
The large sample size meant that all 95% confidence intervals were
less than 0.3 away from percentage proportions and are therefore
not shown.
The data for tables can be found in online Supplementary mate-
rials. The code is available from Mendeley Data (http://dx.doi.org/
10.17632/kv677c2th4.1). Raw data are available from UK Biobank
subject to the usual access procedures (www.ukbiobank.ac.uk).
Role of the funding source
The questionnaire was developed and administered with UK
Biobank funding. Individual authors were funded by their institu-
tions and research grants as detailed below. No funding body influ-
enced the study design or the writing of this article. M.H. had access
to all data through a standard data sharing agreement (Material
Transfer Agreement) with UK Biobank and had final responsibility
for the decision to submit the article for publication.
Results
The setting, recruitment and methods of selection of participants in
UK Biobank have been published elsewhere.1,9 For the MHQ study,
339 092 participants were sent an email invitation, and 157 366
(46% of those emailed) fully completed the questionnaire by
August 2017 –whichmeans that theMHQ currently has 31% cover-
age of the UK Biobank cohort. Figure 1 shows a flow chart of the UK
Biobank participants who completed the MHQ. The median time
for completion was 14 min, and 82% of respondents completed
the questionnaire in under 25 min.
Supplementary Table SM2 shows participant characteristics for
all UK Biobank participants and those who completed the MHQ,
compared with population-level data for UK residents in the same
age range. Participants were different from the whole UK Biobank
cohort and the general population in that they were better educated
(e.g. 45% held a degree v. 32% of UK Biobank participants v. 23% in
the census), of higher socioeconomic status according to job type,
and healthier (longstanding illness or disability 28% v. 32% v.
37%), with lower rates of current smoking.
As shown in Table 1, 34% of respondents reported they had
received at least one psychiatric diagnosis from a professional at
some time, and 12% had received two or more. Themost commonly
reported diagnosis was depression, followed by ‘anxiety or nerves’.
Data were compared with the HSE, because this annual survey
aims to report data that is a representative estimate for the popula-
tion in England through its sample and weighting.20 The compari-
son shows that the pattern and prevalence of diagnosis is similar; for
example, a depression diagnosis was self-reported by 21% of indivi-
duals in both samples, eating disorders by around 1%, and bipolar-
related disorders by around 0.5%. The definition in the MHQ dif-
fered from that in the HSE for anxiety (MHQ definition was
broader) and addiction (MHQ did not require professional diagno-
sis), and the higher overall prevalence in the UK Biobank MHQ
compared with the HSE (35% v. 28%) may be due to those wider
definitions.
As shown in Table 2, 35% of participants met criteria for one or
more operationally defined syndromes. The most common was life-
time depression at 24%, followed by anxiety disorder and alcohol
use disorder (both 7%), PTSD (6%), unusual experiences (5%)
and self-harm (4%). Hypomania/mania was the least common,
for 2% of respondents. As shown in Supplementary Table SM3,
women were more likely than men to have a history of one or
more of the defined syndromes (39% v. 30%), particularly depres-
sion, anxiety or PTSD. Men were more likely than women to have
an alcohol use disorder (10% v. 5%), and there was little difference
in the rate of report of unusual experiences (both 5%). Table 2 also
shows the substantial comorbidity of defined syndromes. Notably,
around three-quarters of participants who met criteria for lifetime
anxiety disorder also met criteria for lifetime depression, while indi-
viduals with PTSD had at least a two-fold increase in lifetime preva-
lence of all other syndromes. Alcohol use disorder appeared less
related to the others.
The proportion of respondents meeting criteria for the lifetime
occurrence of at least one of depression, anxiety, unusual experi-
ences and addiction varied according to age and gender (Fig. 2),
from 16% in men over 75 years old to 42% in women aged 45–54
years. Respondents with any of these lifetime syndromes were
more likely than those without to live in areas of higher deprivation,
especially if they had bipolar disorder or reported addiction
(Table 3). They were also more likely to have had adverse life
events and to have met criteria for loneliness and, to a lesser
extent, social isolation. They were more likely to have smoked cigar-
ettes and/or used cannabis, and to have had a ‘longstanding illness’
at baseline (although the presence of a mental disorder may have
been the illness to which the participants referred in some cases).
Achieving recommended levels of physical activity did not appear
to be associated with any of the syndromes.
The Supplementary materials have a section on mood disorder,
showing the results of analyses of MHQ participants by likely
disorder categories (Supplementary Figure MD1). Supplementary
Table MD1 shows the features of these groups. The characteristics
of people who meet diagnostic criteria for depression appear to
be shared by those with subthreshold depressive symptoms.
Supplementary Table MD2 shows comorbidity, and demonstrates
a gradient effect in the presence of a non-depression syndrome
rising from 7% in no depression to 43% in recurrent depression.
Supplementary Table MD3 shows an association between the pres-
ence of lifetime unipolar depression or bipolar affective disorder and
worse scores for current mental health.
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Discussion
This paper has described the development, implementation and
principal descriptive findings from the UK Biobank MHQ. The
implementation of this questionnaire demonstrates that a web-
based questionnaire is an acceptable means of collecting mental
health information at low cost and large scale. Although the data
collection methods might result in more limited data acquisition
than conventional interview methods, with associated uncertainties
in true diagnostic categorisation, we suggest that the survey
achieved an acceptable trade-off between depth of phenotypic infor-
mation and scale of sample size.
The MHQ achieved a participation rate of 31% of the original
UK Biobank participants and 46% of those emailed. This response
rate is substantially higher than previous UK Biobank question-
naires, largely owing to the attention paid to ensuring the accept-
ability of the invitation and questionnaire and the efficient use of
reminders. Those who completed the MHQ appeared to be better
educated and to have higher socioeconomic employment status
than those recruited into UK Biobank overall, and the UK popula-
tion. Despite this, we found that rates of self-reported diagnoses
were similar to population estimates from the HSE. The patterns
of association between disorders and demographics were also
broadly as predicted by previous research, which adds to the face
validity of the questionnaire. For example, depression and anxiety
were more common in women, while addiction and alcohol
misuse were more common in men, and all disorders were less
common in respondents older than 65 years. The decrease in preva-
lence of lifetime disorder with increasing age has been previously
noted in cross-sectional studies, although the causes and implica-
tions are not clearly understood.21,22
The ‘healthy volunteer’ selection bias within the UK Biobank
has previously been explored.23 The influence of selection biases
on disease prevalence are likely to be particularly strong for
mental disorders, where disorder status or symptoms may influence
participation in research,24,25 and non-participation has also been
associated with many risk factors for these disorders, including
polygenic risk.26 Therefore, the results of the MHQ should not be
used to provide prevalence estimates. However, the pattern of the
measured risk factors among the participants with mental disorders
in the MHQ, including neuroticism, trauma, loneliness and housing
tenure, was in accordance with established literature, supporting the
use of the data to study the relationships between exposures and
outcomes. Previous work on health surveys with selection bias
due to non-participation, including UK Biobank, have indicated
that although they can be used to give estimates of associ-
ation,11,24,27 bias may occur in some cases.28,29 For example, the
relative under-participation of unskilled workers in the MHQ
(around 21% of that expected) could mask an association with a
variable that was related to unskilled work.
Invited at baseline (n=8767661)
Recruited at baseline (n=503328)
Not sent an email invitation (n=164126)
Primary reason for not receiving email1
Responded without being sent an email invite (n=433)
Died (n=14228)
Withdrawn (n=1020)
No valid email address (n=147828)
Do not wish to receive emails from UK Biobank (n=459)
Do not wish to provide further data (n=150)
Other reasons (n=8)
Sent email invitation (n=339092)2
Response received following email invite 
(n=156,933)3
Did not respond (n=182159)3 
Primary reason for non-response1
Died (n=3346)
Withdrawn (n=12)
Do not want to complete questionnaire (n=873)
Unknown (n=177928)
1Participants could have multiple reasons for not being sent an email, or 
for not responding. For the purposes of this flowchart, we have identified 
the most important reason people were not sent an email. 
2Emails were sent up to and including 24 July 2017. 110 email invites 
have been sent since this date – any resultant data are not included here. 
3Cut off date for providing responses was 27 July 2017.
Response received via participant website 
(n=433)3 
Fig. 1 Flowchart of UK Biobank participants from invitation to completion of mental health questionnaire. Invitations were based on NHS
registration, age and location. Numbers correct for July 2017.
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Strengths and limitations
We developed a questionnaire through a consensus approach with
clear aims of capturing enough data to characterise participants as
having a lifetime history of depression and other phenotypes.
Validated instruments were used where possible. The consortium
working on the questionnaire included mental health researchers
and members of the UK Biobank team working in collaboration
to develop the optimum approach. The derived variables of likely
categorical diagnoses will be added to the UK Biobank resource,
facilitating those less familiar with mental health to use the results
efficiently.
The ‘healthy volunteer’ effect may limit applications of the data.
Owing to restrictions of time and space, the questionnaire was
limited in the topics it could cover. The focus of the questionnaire
was on categorical diagnoses rather than dimensional traits, which
will tend to confirm conventional ICD/DSMnosology of psychiatric
disorder and may not suit some research.30 In particular, tools were
chosen that are based on DSM-IV disorders, which reflects current
practice (for example, National Institute for Health and Care
Excellence guidelines on depression and anxiety use DSM-IV defi-
nitions).31,32 Of the disorders with operational classification, all
would generalise to DSM-5, except PTSD,33 and the concepts are
Table 1 Self-reported previous physician diagnosisa (self-reported without physician diagnosis for addictionb)
UK Biobank MHQ responses
(age 45–82 years)
Health Survey for England
(HSE) (age 45–84 years)
N = 157 366 % in sample N = 3272 Prevalence (95% CI)
All psychotic disorders 723 0.5 11 0.3 (0.2–0.6)
Schizophrenia 157 0.1 NA
Any other type of psychosis or psychotic illness 604 0.4 NA
Depression 33424 21.2 679 20.8 (19.4–22.2)
Mania, hypomania, bipolar or manic-depression 837 0.5 13 0.4 (0.2–0.7)
Anxiety, nerves or generalised anxiety disorderc 22036 14.0 170 5.2 (4.5–6)
Panic attacks 8704 5.5 262 8.0 (7.1–9.0)
Agoraphobia 599 0.4 NA
Social anxiety or social phobia 1962 1.2 NA
Any other phobia (e.g. disabling fear of heights or spiders) 2153 1.4 27 0.8 (0.6–1.2)
Obsessive–compulsive disorder 982 0.6 11 0.3 (0.2–0.6)
Any personality disorder 385 0.2 13 0.4 (0.2–0.7)
All eating disorders 1851 1.2 26 0.8 (0.5–1.2)
Anorexia nervosa 891 0.6 NA
Bulimia nervosa 503 0.3 NA
Psychological over-eating or binge-eating 707 0.4 NA
Autism, Asperger’s or autistic spectrum disorder 223 0.1 NA
Attention-deficit or attention-deficit hyperactivity disorder 133 0.1 4 0.1 (0–0.3)
Any addiction or dependence 9386 6.0 NA
Alcohol or drug addictionb 5002 3.2 30 0.9 (0.6–1.3)
Physical alcohol dependence 946 0.6 NA
Summary
None of above 103346 65.7 2356 72.0 (70.4–73.5)
One or more of the above 54020 34.3 916 28.0 (26.5–29.6)
Two or more of the above 19400 12.3 NA
NA, not reported.
a. UK Biobank participants were asked: ‘Have you been diagnosed with one ormore of the followingmental health problems by a professional, even if you don’t have it currently? (tick all that
apply): By professional we mean: any doctor, nurse or person with specialist training (such as a psychologist or therapist). Please include disorders even if you did not need treatment for
them or if you did not agree with the diagnosis’. HSE participants were asked to identify all the mental health conditions they had experienced, then asked whether they had been told by a
doctor, psychiatrist or professional that they had it.
b. UK Biobank participants were asked: ‘Have you been addicted to or dependent on one or more things, including substances (not cigarettes/coffee) or behaviours (such as gambling)?’ HSE
definition of addiction includes physician diagnosis.
c. HSE participants were asked about generalised anxiety disorder, and not about anxiety and nerves more generically.
Table 2 Comorbidity between operationally defined syndromes
Overall
Prevalence
Comorbidity
Depression
Hypomania/
mania
Anxiety
disorder
Unusual
experiences Self-harm
Alcohol use
disorder PTSD
Total= 55570 (35%) 37434 (24%) 2396 (2%) 11111 (7%) 7803 (5%) 6872 (4%) 10911 (7%) 10064 (6%)
Lifetime history Depressiona 37434 (24%) 1550 (4%) 8444 (23%) 3649 (10%) 4240 (11%) 3405 (9%) 6373 (17%)
Hypomania/maniab 2396 (2%) 1550 (65%) 778 (32%) 598 (25%) 453 (19%) 327 (14%) 657 (27%)
Anxiety disorder (GAD)c 11111 (7%) 8444 (76%) 778 (7%) 1551 (14%) 1704 (15%) 1286 (12%) 3274 (29%)
Unusual experiencesd 7803 (5%) 3649 (47%) 598 (8%) 1551 (20%) 1225 (16%) 768 (10%) 1594 (20%)
Self-harme 6872 (4%) 4240 (62%) 453 (7%) 1704 (25%) 1225 (18%) 959 (14%) 1719 (25%)
Current Alcohol use disorderf 10911 (7%) 3405 (31%) 327 (3%) 1286 (12%) 768 (7%) 959 (9%) 1360 (12%)
PTSDg 10064 (6%) 6373 (63%) 657 (7%) 3274 (33%) 1594 (16%) 1719 (17%) 1360 (14%)
Percentages refer to the proportion of participants with the row syndrome who also have column syndrome. See lettered table notes, and Supplementary Appendix 2 for case definitions.
GAD, generalised anxiety disorder; PTSD, post-traumatic stress disorder.
a. Criteria met for major depressive disorder on CIDI-SF lifetime.
b. Criteria met for hypomania/mania lasting for at least one week.
c. Criteria met for generalised anxiety disorder on CIDI-SF lifetime.
d. Reported potential hallucination or delusion at any point in their life.
e. Reported deliberate self-harm at some point in their life, asked to report self-harm ‘whether or not you meant to end your life’.
f. Criteria met for moderate alcohol use disorder on AUDIT during the past year.
g. Criteria met for post-traumatic stress disorder on PCL-6 in the past month.
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valid for ICD-10 disorders, although the threshold of disorder may
be different, e.g. depression is diagnosed with fewer symptoms in
DSM than in ICD.31 The questionnaire was heavily reliant on par-
ticipant report, which may be affected by the stigma of reporting
psychiatric symptoms, and tends to underestimate lifetime preva-
lence through forgetting or re-evaluating distant events.11,21,34 We
hope that some of these shortcomings can be addressed in the
future by a more fine-grained analysis of the MHQ data, supple-
mented with other data from UK Biobank to create a richer
picture of mental health in the cohort.
Conclusions
UK Biobank offers a unique opportunity to research common dis-
orders in a well-characterised longitudinal cohort of UK adults.
A detailed MHQ has now been completed by 157 366 participants,
including self-report, operationally defined lifetime disorder status,
and detailed phenotype information onmood disorder. The propor-
tion of cases and the patterns of participants experiencing symp-
toms and disorders was as expected, despite a ‘healthy volunteer’
selection bias. Future work on mental health phenotyping for UK
Biobank will include validation of Hospital Episode Statistics for
mental health diagnoses, validation of general practice records,
and triangulation of health record and questionnaire data.
Examples of existing projects utilising the UK Biobank MHQ can
be seen in Supplementary Appendix 3, with a searchable database
of approved research (http://www.ukbiobank.ac.uk/approved-
research/).
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Fig. 2 Proportion of respondents positive for one or more of
depression (and bipolar disorder), generalised anxiety disorder,
unusual experiences and addiction according to lifetime diagnostic
criteria. By age and gender.
Table 3 Socioeconomic factors by status for lifetime occurrence (people may be included in more than one category)
No ‘lifetime’
criteria meta
N = 102 901
Depressionb
N = 37 434
Bipolar
type 1c
N = 931
Anxiety
disorder (GAD)b
N = 11 111
Unusual
experiencesd
N = 7803
Addictione
N = 9386
Personal characteristics
Agef 45–54 14364 (13%) 7145 (19%) 228 (24%) 2348 (21%) 1485 (19%) 2013 (21%)
55–64 33307 (31%) 14809 (40%) 417 (45%) 4470 (40%) 2904 (37%) 3428 (37%)
65–74 51705 (48%) 13739 (37%) 261 (28%) 3892 (35%) 2960 (38%) 3466 (37%)
75+ (oldest is 82) 9376 (9%) 1741 (5%) 25 (3%) 401 (4%) 454 (6%) 479 (5%)
Gender Female 57556 (53%) 25815 (69%) 532 (57%) 7404 (67%) 4718 (60%) 4556 (49%)
Ethnicity White 105072 (97%) 36297 (97%) 892 (96%) 10749 (97%)c 7503 (96%) 9037 (96%)
Townsend Deprivation Scoreg Most deprived (TDS ≥ +2) 11783 (11%) 5656 (15%) 201 (22%) 1856 (17%) 1426 (18%) 1941 (21%)
Highest qualification Degree 48700 (45%) 16939 (45%) 425 (46%) 5071 (46%) 3646 (47%) 4531 (48%)
Housing tenure Renth 4162 (4%) 2906 (8%) 155 (17%) 1026 (9%) 854 (11%) 1109 (12%)
Known risk factors
Neuroticism scorei Mean (s.d.) 3.2 (2.8) 5.6 (3.3) 3.8 (3.1) 7.1 (3.3) 5.2 (3.5) 5.4 (3.5)
Adverse life experiences Childhood screenj 43913 (40%) 21144 (56%) 638 (69%) 6931 (62%) 4783 (61%) 5800 (62%)
Adult screenk 50226 (46%) 23893 (64%) 685 (74%) 7581 (68%) 4783 (61%) 6303 (67%)
Trauma exposurel 50771 (47%) 22166 (59%) 665 (71%) 6877 (62%) 5439 (70%) 6278 (67%)
Social connection Lonelinessi,
m
2976 (3%) 2367 (6%) 94 (10%) 971 (9%) 570 (7%) 669 (7%)
Social isolationi 7793 (7%) 3623 (10%) 126 (14%) 1173 (11%) 931 (12%) 1200 (13%)
Illness Longstanding illness,
disability or infirmityi
26341 (24%) 13363 (36%) 503 (54%) 4581 (41%) 3242 (42%) 3588 (38%)
Health-related behaviours
Smoking statusi Current 6235 (6%) 3638 (10%) 158 (17%) 1194 (11%) 837 (11%) 1916 (20%)
Former 36425 (33%) 13927 (37%) 323 (35%) 4009 (36%) 2943 (38%) 4893 (52%)
Never 65827 (61%) 19786 (53%) 448 (48%) 5883 (53%) 4003 (51%) 2547 (27%)
Cannabis use (lifetime) Daily 868 (1%) 914 (2%) 63 (7%) 346 (3%) 258 (3%) 867 (9%)
Ever, but not daily 19675 (18%) 9607 (26%) 299 (32%) 2818 (25%) 2312 (30%) 3487 (37%)
Never 88209 (81%) 26913 (72%) 569 (61%) 7947 (72%) 5233 (67%) 5032 (54%)
Physical activityi Moderate activity ≥ three
times a week
93331 (86%) 31389 (84%) 751 (81%) 9253 (83%) 6522 (84%) 7796 (83%)
See lettered table notes, and Supplementary Appendix 2 for full case definitions.
a. Criteria not met for depression, GAD, unusual experiences or addiction.
b. Criteria met for disorder on CIDI-SF lifetime.
c. Criteria met for both lifetime depression and lifetime mania.
d. Reported potential hallucination or delusion at any point in their life.
e. Positively endorsed: ‘Have you been addicted to or dependent on one or more things, including substances (not cigarettes/coffee) or behaviours (such as gambling)?’
f. Age when mental health questionnaire released, derived from date of birth.
g. Townsend Material Deprivation Score is based on postcode areas.
h. Renting in the private sector and renting social housing combined.
i. From baseline assessment 2007–10.
j. Criteria met for possible abuse or neglect on Childhood Trauma Screener.
k. Criteria met for adverse situations as an adult: lack of confiding relationship, abusive relationships and money problems.
l. Reports one or more of six situations that are known to be triggers for trauma-related disorders.
m. There is some overlap between the adult screen and loneliness screen, which both ask about confiding relationships: adult screen includes lack of confiding relationship over the adult
lifetime; loneliness includes lack of confiding relationship at the time of baseline assessment.
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This study also demonstrates the substantial burden of mental
disorders. Given the known effects of mental health on physical
health, mental health data should interest researchers from every
biomedical specialty looking at associations with health and
disease. This study suggests that UK Biobank could be a powerful
tool for such studies, and, since it is open to all bona fide health
researchers for work in the public good, we hope this study will
inspire both existing and new users of UK Biobank.
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